Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients

Phase 2

Completed

• Conditions: Colorectal Neoplasms; Rectal Diseases; RAS and BRAF Wild-type; Digestive System Neoplasms; Neoplasms; Colonic Diseases; Intestinal Diseases; Colorectal Cancer; Intestinal Neoplasms; Gastrointestinal Neoplasms
• Interventions: Drug: Anlotinib Hydrochloride; Drug: Capecitabine; Drug: Oxaliplatin

• Registration Number: NCT04080843
• Lead Sponsor: Zhejiang University

Brief Summary

This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF wild-type patients with Metastatic Colorectal Carcinoma(CRC) as 1st Therapy. After 6 cycles of combined therapy, patients will receive capecitabine and anlotinib as maintenance therapy until tumor progression.In order to observe and evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules combined with CAPEOX in treatment of patients with mCRC. The patients who are pathologically confirmed as RAS and BRAF wild-type mCRC will be enrolled.

Condition or disease Invention/treatment Phase Colorectal Cancer Drug: Anlotinib Hydrochloride Drug: Capecitabine Drug: Oxaliplatin Phase 2

Detailed Description

This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF wild-type patients with Metastatic Colorectal Carcinoma(CRC) as 1st Therapy. After 6 cycles of combined therapy, patients will receive capecitabine and anlotinib as maintenance therapy until tumor progression.In order to observe and evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules combined with CAPEOX in treatment of patients with Metastatic Colorectal Carcinoma(mCRC).Primary Efficacy Endpoint: Objective Response Rate (ORR), Secondary Efficacy Endpoints: Progression free survival (PFS) (According to RECIST Version 1.1), Disease Control Rate (DCR) and duration of response(DoR). Safety and tolerance will be evaluated by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 4.0.

Study Timeline

• Study First Submitted: 2019-09-03
• Study First Submitted QC: 2019-09-05
• Study First Posted: 2019-09-06
• Study Start: 2019-11-15
• Primary Completion: 2022-06-01
• Status Verified: 2022-07
• Study Completion: 2022-07-01
• Last Update Submitted: 2022-07-12
• Last Update Posted: 2022-07-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• At least one measurable lesion (the length of spiral CT scan (> 10mm) meets the requirements of RESCIST 1.1) is found in patients with HCC confirmed by histopathology or cytology or who meet the clinical diagnostic criteria.
• ≥ 18 and ≤ 75 years of age
• ECOG performance status of 0-1
• No prior treatment for advanced disease (adjuvant therapy allowed)
• Life expectancy of at least 3 months
• The main organs are functioning normally.
• Neutrophils count =/> 1.5 x 109/L, platelets count =/> 100 x 109/L, HGB =/> 90 g/L
• total bilirubin =/< 1.5 x UNL • SGOT and SGPT =/< 2.5 x UNL (=/< 5 x UNL in patients with liver metastases)
• Creatinine =/< 1.5 x UNL
• Patients who are molecularly diagnosed as having RAS and BRAF wild-type mCRC are Histologically/cytologically confirmed as advanced, colorectal cancer.
• Subjects volunteered to join the study, signed informed consent, good compliance, with follow-up.

Exclusion Criteria

• Pregnant or lactating women.
• Active or untreated CNS metastases as determined by CT or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments.
• Patients with hypertension who could not be well controlled by antihypertensive drugs (systolic blood pressure > 150 mmHg, diastolic blood pressure > 100 mmHg), patients with myocardial infarction, arrhythmias with poor control (including QTC interval > 450 ms) and cardiac insufficiency of grade II according to NYHA standard.
• with bleeding tendency or undergoing thrombolysis or anticoagulation therapy.
• serious uncontrolled intercurrence infection.
• Proteinuria ≥ 2+ (1.0g/24hr).
• Have evidence or a history of bleeding tendency within two months of the enrollment, regardless of seriousness.
• Within 6 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc.
• Have a history of mental illness or psychotropic drug abuse.
• Patients with a history of immunodeficiency(or autoimmue disease), or other acquired congenital immunodeficiency diseases, or a history of organ transplantation and hematopoietic stem cell transplantation.
• Patients who are allergic to components of Capecitabine preparations, Oxaliplatin injection and anlotinib preparations.
• According to the researchers' judgment, there are serious concomitant diseases that endanger patient safety or prevent patients from completing the study.
• Patients who have received prior systemic chemotherapy, targeted therapy, immunity therapy or any medication within 30 days.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Group A	Anlotinib Hydrochloride	Patients in the study group will receive the following treatment: 21 days as a treatment cycle, Anlotinib 12 mg/day, Orally(D1-D14); Capecitabine 850 mg/m2,Orally(D1-D14), Bid; Oxaliplatin 130 mg/m2, iv(D1). If anlotinib is not tolerated(except Hand-foot skin reaction), the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again. After 6 cycles of combined therapy, patients will receive capecitabine and anlotinib as maintenance therapy until tumor progression.
Group A	Capecitabine	Patients in the study group will receive the following treatment: 21 days as a treatment cycle, Anlotinib 12 mg/day, Orally(D1-D14); Capecitabine 850 mg/m2,Orally(D1-D14), Bid; Oxaliplatin 130 mg/m2, iv(D1). If anlotinib is not tolerated(except Hand-foot skin reaction), the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again. After 6 cycles of combined therapy, patients will receive capecitabine and anlotinib as maintenance therapy until tumor progression.
Group A	Oxaliplatin	Patients in the study group will receive the following treatment: 21 days as a treatment cycle, Anlotinib 12 mg/day, Orally(D1-D14); Capecitabine 850 mg/m2,Orally(D1-D14), Bid; Oxaliplatin 130 mg/m2, iv(D1). If anlotinib is not tolerated(except Hand-foot skin reaction), the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again. After 6 cycles of combined therapy, patients will receive capecitabine and anlotinib as maintenance therapy until tumor progression.

Primary Outcome Measures

Name	Time	Method
Objective response rate(ORR)	Every 2 weeks until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months	using RECIST version 1.1

Secondary Outcome Measures

Name	Time	Method
Progression-free survival (PFS)	every 2 weeks until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months	using RECIST version 1.1
Disease control rate (DCR)	every 2 weeks until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months	using RECIST version 1.1
Duration of Response (DoR)	every 2 weeks until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months	using RECIST version 1.1
Safety: NCI CTC AE Version 4.0.3	from day 1 of first dosing to 30 days after permanent discontinuation of Anlotinib	Safety will be evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTC AE Version 4.0.3

Trial Locations

Locations (2)

Zhejiang Cancer Hospital; 🇨🇳 Hangzhou, Zhejiang, China

The Second Affiliated Hospital of Zhejiang University; 🇨🇳 Hangzhou, Zhejiang, China